首页> 外文期刊>Annals of surgical oncology >Selection for Resection of Hepatocellular Carcinoma and Surgical Strategy:Indications for Resection,Evaluation of Liver Function,Portal Vein Embolization,and Resection
【24h】

Selection for Resection of Hepatocellular Carcinoma and Surgical Strategy:Indications for Resection,Evaluation of Liver Function,Portal Vein Embolization,and Resection

机译:肝细胞癌切除的选择和手术策略:切除的指征,肝功能评估,门静脉栓塞和切除

获取原文
获取原文并翻译 | 示例
       

摘要

Among the potentially curative treatment options for hepatocellular carcinoma (HCC),liver resection is widely considered the mainstay of curative therapy. An important aspect of the morbidity,mortality, and long-term outcome of liver resection for HCC relates to patient selection. Choice of treatment primarily depends on tumor stage and the functional status of the liver because most patients with HCC harbor chronic liver disease.1 For this reason,when compared with percutaneous ablation therapies or tran-sarterial chemoembolization (TACE), surgery has a higher risk as a result of removal of functioning liver parenchyma. Careful assessment of the clinical severity of cirrhosis and the liver functional reserve is therefore pivotal to ensure suitable selection of appropriate candidates for resection#
机译:在肝细胞癌(HCC)的潜在治疗选择中,肝脏切除术被广泛认为是治疗的主要手段。肝癌肝切除的发病率,死亡率和长期结局的重要方面与患者选择有关。治疗的选择主要取决于肿瘤的分期和肝脏的功能状态,因为大多数HCC患者都患有慢性肝病。1因此,与经皮消融疗法或经皮sar石化学栓塞(TACE)相比,手术的风险更高。由于去除了功能性肝实质。因此,认真评估肝硬化的临床严重程度和肝功能储​​备对于确保适当选择合适的切除对象至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号